Featured Research

from universities, journals, and other organizations

Poorer outcomes linked with certain hormone for patients with early-stage chronic kidney disease

Date:
June 14, 2011
Source:
JAMA and Archives Journals
Summary:
Patients in the early stages of chronic kidney disease who had elevated levels of the endocrine hormone fibroblast growth factor 23 (that regulates phosphorus metabolism) had an associated increased risk of end-stage renal disease and death, according to a new study.

Patients in the early stages of chronic kidney disease who had elevated levels of the endocrine hormone fibroblast growth factor 23 (that regulates phosphorus metabolism) had an associated increased risk of end-stage renal disease and death, according to a study in the June 15 issue of JAMA.

Related Articles


Circulating levels of fibroblast growth factor 23 (FGF-23) increase progressively as kidney function declines. A high level of FGF-23 is associated with mortality in patients with end-stage renal disease, but little is known about its relationship with adverse outcomes in the larger population of patients with earlier stages of chronic kidney disease, according to background information in the article.

Tamara Isakova, M.D., M.M.Sc., of the University of Miami Miller School of Medicine, and colleagues examined the relationship between elevated FGF-23 levels and risk of death and end-stage renal disease in 3,879 individuals with chronic kidney disease stages 2 through 4. The participants were enrolled in the Chronic Renal Insufficiency Cohort between June 2003 and September 2008.

At study enrollment, the average estimated glomerular filtration rate (GFR; measure of the kidneys' ability to filter and remove waste products) was 42.8 mL/min/1.73 m2. During a median (midpoint) follow-up of 3.5 years, 266 participants died and 410 reached end-stage renal disease. The researchers found that median FGF-23 levels were significantly higher in those who died or reached end-stage renal disease than in those who remained event-free. "Adjusting for demographic characteristics, estimated GFR and other chronic kidney disease-specific risk factors did not alter the relationship between elevated FGF-23 levels and risk of death observed in unadjusted analyses. Participants in the highest vs. the lowest quartile demonstrated a 4.3-fold greater risk of death, and the intermediate quartiles demonstrated intermediate risks," the researchers write. In the fully adjusted models, the graded increase in risk of death persisted across the spectrum of FGF-23 levels.

Reduced estimated GFR was the strongest predictor of end-stage renal disease in fully adjusted analysis, and estimated GFR modified the relationship between FGF-23 and risk of end-stage renal disease. "Although the median FGF-23 was higher in more advanced chronic kidney disease, elevated levels of FGF-23 were independently associated with greater risk of end-stage renal disease in participants with baseline estimated GFR between 30 and 45 mL/min/1.73 m2 and 45 mL/min/1.73 m2 or higher but not in those with estimated GFR lower than 30 mL/min/1.73 m2. In contrast, the risk of death according to FGF-23 was homogenously significant across categories of estimated GFR," the authors write.

The researchers note that FGF-23 unexpectedly was more strongly associated with mortality than traditional cardiovascular disease- and chronic kidney disease-specific risk factors, most notably, reduced estimated GFR and proteinuria (the presence of excessive protein). "These data emphasize the potential of FGF-23 as a novel risk factor for mortality in chronic kidney disease."

They add that the mechanisms that underlie the association between elevated levels of FGF-23 and mortality are unclear.

"If the results of the current study are confirmed and experimental studies support the hypothesis of direct toxicity of FGF-23, future research should evaluate whether therapeutic or preventative strategies that lower FGF-23 can improve outcomes."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Tamara Isakova et al. JAMA. 2011;305(23):2432-2439. doi: 10.1001/jama.2011.826 Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney Disease. JAMA, 2011;305(23):2432-2439. DOI: 10.1001/jama.2011.826

Cite This Page:

JAMA and Archives Journals. "Poorer outcomes linked with certain hormone for patients with early-stage chronic kidney disease." ScienceDaily. ScienceDaily, 14 June 2011. <www.sciencedaily.com/releases/2011/06/110614161854.htm>.
JAMA and Archives Journals. (2011, June 14). Poorer outcomes linked with certain hormone for patients with early-stage chronic kidney disease. ScienceDaily. Retrieved October 26, 2014 from www.sciencedaily.com/releases/2011/06/110614161854.htm
JAMA and Archives Journals. "Poorer outcomes linked with certain hormone for patients with early-stage chronic kidney disease." ScienceDaily. www.sciencedaily.com/releases/2011/06/110614161854.htm (accessed October 26, 2014).

Share This



More Health & Medicine News

Sunday, October 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
Toxin-Packed Stem Cells Used To Kill Cancer

Toxin-Packed Stem Cells Used To Kill Cancer

Newsy (Oct. 25, 2014) — A Harvard University Research Team created genetically engineered stem cells that are able to kill cancer cells, while leaving other cells unharmed. Video provided by Newsy
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins